Invitation to Conference Call for Updated Clinical Trial Results reported at the International Conference on Malignant Lymphoma
Oslo, Norway, 13 June 2017 Nordic Nanovector ASA (OSE: NANO) will host a conference call on Wednesday, 14 June at 1 pm CET to present updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical trial of Betalutin® in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma. These data will be presented at the International Conference on Malignant Lymphoma (ICML) on 14-17 June in Lugano, Switzerland. Conference call details: The call is scheduled for Wednesday, 14 June 2017 at 1 pm CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start